Copeptin in Aortic Valve Replacement
Completed
- Conditions
- Copeptin in Patients Undergoing Aortic Valve Replacement
- Registration Number
- NCT01648647
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Brief Summary
Copeptin is accepted as a marker of stress. We want to evaluate the preoperative and early postoperative copeptin leavens in patients undergoing different aortic valve procedures
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Patients undergoing surgical aortic valve replacment
- Patients undergoing transcatheter aortic valve replacment
Exclusion Criteria
- denial by patient
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link copeptin levels to outcomes in aortic valve replacement patients?
How does preoperative copeptin measurement compare to other biomarkers in predicting postoperative complications after aortic valve procedures?
Are there specific patient subtypes where copeptin monitoring improves clinical decision-making in aortic valve replacement?
What adverse events are associated with elevated copeptin levels in cardiovascular surgery populations?
How might copeptin-based monitoring influence future combination therapies for aortic valve disease management?
Trial Locations
- Locations (1)
Deutsches Herzzentrum München des Freistaates Bayern, Technische Universität München
🇩🇪Munich, Bavaria, Germany
Deutsches Herzzentrum München des Freistaates Bayern, Technische Universität München🇩🇪Munich, Bavaria, Germany